Global Medical REIT Inc. (NYSE:XRN – Get Free Report) Director Charles Fitzgerald bought 27,600 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $35.94 per share, for a total transaction of $991,944.00. Following the transaction, the director directly owned 124,893 shares in the company, valued at approximately $4,488,654.42. This represents a 28.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Global Medical REIT Stock Performance
XRN opened at $35.15 on Wednesday. The firm’s fifty day simple moving average is $36.54 and its two-hundred day simple moving average is $35.79. Global Medical REIT Inc. has a 52-week low of $29.05 and a 52-week high of $39.93. The company has a market cap of $464.97 million, a price-to-earnings ratio of 9.45 and a beta of 1.09. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 1.68.
Global Medical REIT (NYSE:XRN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.78 earnings per share for the quarter, topping the consensus estimate of $0.83 by $3.95. Global Medical REIT had a net margin of 36.82% and a return on equity of 13.74%. The firm had revenue of $39.75 million during the quarter. Equities analysts anticipate that Global Medical REIT Inc. will post 3.06 earnings per share for the current fiscal year.
Institutional Trading of Global Medical REIT
Analysts Set New Price Targets
A number of equities analysts recently weighed in on XRN shares. BMO Capital Markets boosted their price target on shares of Global Medical REIT from $39.00 to $40.00 and gave the stock a “market perform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded Global Medical REIT from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Compass Point restated a “neutral” rating and set a $38.00 price objective (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Zacks Research upgraded shares of Global Medical REIT to a “hold” rating in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $40.25.
Check Out Our Latest Stock Analysis on XRN
Global Medical REIT Company Profile
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Further Reading
- Five stocks we like better than Global Medical REIT
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.
